Skip to content
TrialScanner

NCT02823405

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1CompletedXFORLead

Registry record

Lead sponsor
X4 Pharmaceuticals
Conditions
Melanoma
Primary completion
Mar 15, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02823405 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02823405: X4P-001 and Pembrolizumab in... | TrialScanner